title: Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy.
abstract: CD45 is a family of transmembrane protein tyrosine phosphatases exclusively expressed by hematopoietic cells and critically involved in the regulation of T cell activation signals. We now demonstrate that three 100-microg doses of anti-CD45RB mAb MB23G2 can induce long-term engraftment of islets into major histcompatibility complex-disparate chemically diabetic mice. Long-term graft survivors (>120 days) were tolerant to new islet allografts from the original donor strain. MB23G2 induced a temporary decrease in number circulating leukocytes but had no effect on leukocyte number in other lymphoid compartments. Histologic examination of allografts from treated and untreated recipients revealed a similar peri-islet infiltration on day 6. Eleven days after transplant, the peri-islet infiltrate in treated animals persisted, but in marked contrast to untreated control animals, there was no insulitis and islet integrity was preserved. The peri-islet infiltrate from treated animals showed a mild increase in CD4 cells, a decrease in CD8 cells, and decreased intensity of CD45RB expression. Treatment of naive animals with anti-CD45RB (MB23G2) resulted in a shift in CD45 isoform expression on T cells with a loss of higher molecular weight isoforms and increased expression of lower molecular weight (CD45R0) isoform. This shift in CD45 isoform expression from CD45RBHi to CD45RBLo was associated with an increase in the intragraft expression of transcripts for interleukin (IL) 4 and IL-10, consistent with the expected activity of this distinct immunoregulatory T cell subset. Antibody-mediated targeting of CD45 may induce tolerance through novel mechanisms and have direct applicability to clinical transplantation in humans.
authors.affiliation: Department of Transplant Surgery, Yale Medical School, New Haven, CT 06520, USA.
authors.forename: G P
authors.initials: GP
authors.lastname: Basadonna
authors.forename: L
authors.initials: L
authors.lastname: Auersvald
authors.forename: C Q
authors.initials: CQ
authors.lastname: Khuong
authors.forename: X X
authors.initials: XX
authors.lastname: Zheng
authors.forename: N
authors.initials: N
authors.lastname: Kashio
authors.forename: D
authors.initials: D
authors.lastname: Zekzer
authors.forename: M
authors.initials: M
authors.lastname: Minozzo
authors.forename: H
authors.initials: H
authors.lastname: Qian
authors.forename: L
authors.initials: L
authors.lastname: Visser
authors.forename: A
authors.initials: A
authors.lastname: Diepstra
authors.forename: A I
authors.initials: AI
authors.lastname: Lazarovits
authors.forename: S
authors.initials: S
authors.lastname: Poppema
authors.forename: T B
authors.initials: TB
authors.lastname: Strom
authors.forename: D M
authors.initials: DM
authors.lastname: Rothstein
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000601:surgery*; D006084:Graft Rejection / Q000517:prevention & control*; D007108:Immune Tolerance; D007167:Immunotherapy; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D017493:Leukocyte Common Antigens / Q000276:immunology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
chemical_list: D000906:Antibodies; D017493:Leukocyte Common Antigens